Tasimelteon
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314205

CAS#: 609799-22-6

Description: Tasimelteon (trade name Hetlioz) is a drug approved by the FDA solely for the treatment of non-24-hour sleep–wake disorder (often designated as N24HSWD) in totally blind adults. It is a selective agonist for the melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, similar to other members of the melatonin receptor agonist class of which ramelteon (2005) and agomelatine (2009) were the first approved.


Chemical Structure

img
Tasimelteon
CAS# 609799-22-6

Theoretical Analysis

MedKoo Cat#: 314205
Name: Tasimelteon
CAS#: 609799-22-6
Chemical Formula: C15H19NO2
Exact Mass: 245.14158
Molecular Weight: 245.32
Elemental Analysis: C, 73.44; H, 7.81; N, 5.71; O, 13.04

Price and Availability

Size Price Availability Quantity
25.0mg USD 150.0 Same day
50.0mg USD 250.0 Same day
100.0mg USD 450.0 Same day
200.0mg USD 750.0 Same day
500.0mg USD 1450.0 Same day
1.0g USD 2450.0 Same day
2.0g USD 3950.0 Same day
5.0g USD 5250.0 2 Weeks
10.0g USD 7650.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Synonym: BMS214778, BMS-214778, BMS 214778, VEC162, VEC-162, VEC 162, Tasimelteon, Hetlioz

IUPAC/Chemical Name: N-(((1R,2R)-2-(2,3-dihydrobenzofuran-4-yl)cyclopropyl)methyl)propionamide

InChi Key: PTOIAAWZLUQTIO-GXFFZTMASA-N

InChi Code: InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1

SMILES Code: CCC(NC[C@H]1[C@H](C2=C3CCOC3=CC=C2)C1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 245.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1: Tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder. Med Lett Drugs Ther. 2014 Apr 28;56(1441):34-5. PubMed PMID: 24759294.

2: Dhillon S, Clarke M. Tasimelteon: first global approval. Drugs. 2014 Mar;74(4):505-11. doi: 10.1007/s40265-014-0200-1. PubMed PMID: 24610704.

3: Traynor K. Tasimelteon approved for circadian disorder in blind adults. Am J Health Syst Pharm. 2014 Mar 1;71(5):350. doi: 10.2146/news140017. PubMed PMID: 24534583.

4: Lankford DA. Tasimelteon for insomnia. Expert Opin Investig Drugs. 2011 Jul;20(7):987-93. doi: 10.1517/13543784.2011.583235. Epub 2011 May 9. Review. PubMed PMID: 21548834.

5: Hardeland R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. Curr Opin Investig Drugs. 2009 Jul;10(7):691-701. PubMed PMID: 19579175.

6: Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, Klerman EB. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. 2009 Feb 7;373(9662):482-91. doi: 10.1016/S0140-6736(08)61812-7. Epub 2008 Dec 4. Erratum in: Lancet. 2009 Apr 11;373(9671):1252. PubMed PMID: 19054552.